logo
  

Innate To Return US & EU Commercialization Rights Of Lumoxiti To AstraZeneca - Quick Facts

Innate Pharma SA (IPHA) said the company will return the US and EU commercialization rights of Lumoxiti to AstraZeneca (AZN.L,AZN). The company licensed the rights to AstraZeneca's Lumoxiti for certain patients with relapsed or refractory hairy cell leukemia in October 2018.

"We've determined that there is low strategic value for us in maintaining Lumoxiti in our portfolio due to lower than anticipated product sales, further compounded by the ongoing COVID-19 pandemic. This has led us to make the decision to re-prioritize our investments in our R&D portfolio," said Mondher Mahjoubi, CEO of Innate Pharma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cryptocurrency Dogecoin's price jumped over 15% on Friday, but later lost some of the gains, after Tesla Inc. (TSLA) CEO Elon Musk announced that the luxury car maker will start accepting the meme cryptocurrency as payment for its merchandise. "Tesla merch buyable with Dogecoin," Musk tweeted on Friday. Dogecoin... US investment bank JPMorgan Chase & Co. reported Friday a profit for the fourth quarter that declined 14 percent from last year, hurt primarily by higher noninterest expense and lower credit reserve releases. Both adjusted earnings per share and revenues for the quarter topped analysts' expectations. Microsoft Corp. said its Board of Directors has initiated a review of the effectiveness of its workplace sexual harassment and gender discrimination policies and practices. The company has hired the law firm of Arent Fox to conduct the review mainly on sexual harassment investigations, including that of co-founder Bill Gates.
RELATED NEWS
Follow RTT